Intrapleural cisplatin for management of malignant pleural effusion in a patient with plasma cell leucaemia.

Abhishek Agarwal, Jagpal Klair, Setu Patolia, Nikhil K Meena

Open access · bronzeAbstract readCase Reports

In one paragraph

Article in BMJ case reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.5field-weighted citation impact, top 29% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

A single institution experience for the management of recurrent pleural effusions with tunneled pleural catheter and its evolution.Therapeutic advances in respiratory disease · 2017
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Abhishek AgarwalCooper University Hospital, Camden, New Jersey, USA.

Jagpal KlairDepartment of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Setu PatoliaUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

Nikhil K MeenaDepartment of Pulmonary and Critical Care Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

University of Arkansas for Medical Sciences · USCooper University Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasma cell leucaemia (PCL) is a rare aggressive form of multiple myeloma. It occasionally involves the pleura, causing malignant pleural effusion (MPE). MPE presents a management dilemma for physicians, given the different treatment options available with varying efficacy and side effects. We report a case of a 64-year-old man with MPE due to PCL, successfully managed with intrapleural cisplatin and a tunnelled pleural catheter. We believe this to be the first report of management of PCL-associated MPE with intrapleural cisplatin.

Indexed as

Antineoplastic AgentsCathetersCisplatinHumansLeukemia, Plasma CellMaleMiddle AgedPlasma CellsPleuraPleural Effusion, MalignantAntineoplastic AgentsCisplatin

Identifiers

PMID26123465

DOI10.1136/bcr-2015-210044

PMCPMC4488616

OpenAlexW2270247346

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.